Despite the proliferation of biotech initial public offerings (IPO) this year – including two that priced yesterday (see the related story in this issue) – Adimab LLC is distinctly disinterested in the public markets. And the Lebanon, N.H., firm can well afford to remain private. Early Friday morning, the company disclosed two more in a string of lucrative deals that catapulted it to profitability just three years after its 2007 launch.

Genentech Inc., a unit of the Roche Group, received the confirmation on lead hematology candidate GA101 (obinutuzumab) it's been awaiting since an interim analysis at the end of January showed marked improvement in progression-free survival (PFS) in a Phase III trial in previously untreated chronic lymphocytic leukemia (CLL).

Shares of Array Biopharma Inc. hit a 52-week high of $7.20 Tuesday morning after the company reported positive findings from its randomized Phase II trial of oral CRTh2 antagonist ARRY-502 in mild to moderate persistent allergic asthma. The compound hit the primary endpoint – significant improvement in pre-bronchodilator forced expiratory volume in one second (FEV1), compared to placebo – across the study population and in a predefined Th2 biomarker subset that represented half of treated patients.

After pushing shares of Isis Pharmaceuticals Inc. to a 52-week high in late June on the first Phase II data of antisense drug Isis-ApoCIIIRx, investors were more cautious Monday when the company reported additional Phase II data on patients with high to severely high triglycerides on stable doses of fibrates.

A small biotech buy earlier this year could someday reap big rewards for Ignyta Inc., a San Diego firm that is integrating targeted drug discovery and development with companion diagnostics for patient stratification.

With the migration of biotechs to the public markets during the second quarter of 2013, Cowen and Co. LLC theorized in its recent biotech quarterly report that merger and acquisition (M&A) activity in the sector might be suppressed this year.

As promised, Eli Lilly and Co. is making another run at Alzheimer's disease (AD) with its Phase III candidate solanezumab (sola), this time in the mild form of the disease.

Robust Phase I findings for ALN-TTRsc, a subcutaneously administered RNAi therapy targeting transthyretin (TTR) in TTR-mediated amyloidosis, propelled Alnylam Pharmaceuticals Inc. to a 52-week high Thursday morning.